SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* Cohen Neil Harris (Last) (First) (Middle) C/O CHEMOMAB THERAPEUTICS LTD. 1 KENDALL SQ, BLDG 1400E, STE 14-105 (Street) CAMBRIDGE MASSACHUSETTS 02139 (City) (State) (Zip) UNITED STATES (Country)	2. Issuer Name and Ticker or Trading Symbol Chemomab Therapeutics Ltd. [ CMMB ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	2a. Foreign Trading Symbol
	3. Date of Earliest Transaction (Month/Day/Year) 08/27/2026	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
	4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/27/2026		S		1,304	D	$2.85	34,000	D
American Depositary Shares	08/28/2026		S		1,000	D	$2.8	33,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy American Depositary Shares)	$52.8	07/16/2020		A		172		(1)	07/16/2030	American Depositary Shares	172	$0	172	D
Stock option (right to buy American Depositary Shares)	$109.04	04/19/2021		A		2,971		(2)	04/19/2031	American Depositary Shares	2,971	$0	3,143	D
Stock option (right to buy American Depositary Shares)	$14.12	03/07/2022		A		1,705		(3)	03/07/2032	American Depositary Shares	1,705	$0	4,848	D
Stock option (right to buy American Depositary Shares)	$6.48	03/21/2023		A		1,714		(4)	03/21/2033	American Depositary Shares	1,714	$0	6,562	D
Stock option (right to buy American Depositary Shares)	$2.96	03/18/2024		A		2,520		(5)	03/18/2034	American Depositary Shares	2,520	$0	9,082	D
Stock option (right to buy American Depositary Shares)	$6.16	03/16/2025		A		3,821		(6)	03/16/2035	American Depositary Shares	3,821	$0	12,903	D
Stock option (right to buy American Depositary Shares)	$2.14	03/16/2026		A		5,172		03/16/2027	03/16/2036	American Depositary Shares	5,172	$0	18,075	D

Explanation of Responses:

1. The options reported in this row were granted to the Reporting Person by the Issuer on July 16, 2020, and are fully vested and exercisable as of the date of this report.

2. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.

3. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.

4. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.

5. The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.

6. The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.

	/s/ Neil Cohen	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)